TrialBMC infectious diseases2025

DRTB-HDT: a randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis.

Nestani Tukvadze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.